300 related articles for article (PubMed ID: 22573721)
1. European perspective on multiple myeloma treatment strategies: update following recent congresses.
Ludwig H; Avet-Loiseau H; Bladé J; Boccadoro M; Cavenagh J; Cavo M; Davies F; de la Rubia J; Delimpasi S; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Hess U; Mellqvist UH; Moreau P; San-Miguel J; Sondergeld P; Sonneveld P; Udvardy M; Palumbo A
Oncologist; 2012; 17(5):592-606. PubMed ID: 22573721
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
Ludwig H; Beksac M; Bladé J; Cavenagh J; Cavo M; Delforge M; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Harousseau JL; Hess U; Kropff M; Leal da Costa F; Louw V; Magen-Nativ H; Mendeleeva L; Nahi H; Plesner T; San-Miguel J; Sonneveld P; Udvardy M; Sondergeld P; Palumbo A
Oncologist; 2011; 16(4):388-403. PubMed ID: 21441574
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide for bortezomib-resistant multiple myeloma.
Briani C; Berno T; Campagnolo M; Zambello R
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824906
[No Abstract] [Full Text] [Related]
5. Lenalidomide efficacy in bortezomib-resistant myeloma.
Gozzetti A; Crupi R; Defina M; Bocchia M
Nat Rev Clin Oncol; 2010 Sep; 7(9):. PubMed ID: 20824907
[No Abstract] [Full Text] [Related]
6. Novel agents for multiple myeloma treatment.
Ribatti D; Vacca A
Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
[No Abstract] [Full Text] [Related]
7. Clinical management of myeloma--state of the art.
Harousseau JL
Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib and lenalidomide effective in myeloma.
Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
[No Abstract] [Full Text] [Related]
10. Current multiple myeloma treatment strategies with novel agents: a European perspective.
Ludwig H; Beksac M; Bladé J; Boccadoro M; Cavenagh J; Cavo M; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Harousseau JL; Hess U; Ketterer N; Kropff M; Mendeleeva L; Morgan G; Palumbo A; Plesner T; San Miguel J; Shpilberg O; Sondergeld P; Sonneveld P; Zweegman S
Oncologist; 2010; 15(1):6-25. PubMed ID: 20086168
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: novel approaches for relapsed disease.
Lonial S
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
[TBL] [Abstract][Full Text] [Related]
12. Maintenance treatment in multiple myeloma.
Harousseau JL
Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
[No Abstract] [Full Text] [Related]
13. New treatments in multiple myeloma: beyond optimal treatment.
Harousseau JL
Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
[No Abstract] [Full Text] [Related]
14. Treatment of relapsed and refractory myeloma.
Kaufman J; Gleason C; Lonial S
Curr Hematol Malig Rep; 2009 Apr; 4(2):99-107. PubMed ID: 20425421
[TBL] [Abstract][Full Text] [Related]
15. Novel agents in the frontline management of multiple myeloma.
Loong HH
Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
[TBL] [Abstract][Full Text] [Related]
16. Clinical update: novel targets in multiple myeloma.
Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A
Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
[TBL] [Abstract][Full Text] [Related]
18. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
19. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
[TBL] [Abstract][Full Text] [Related]
20. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]